retatrutide clinical trial results 2025 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN TRIALS, is showing incredible results, with some Retatrutide Phase 3: 60% Achieved

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Similarly, liraglutide for diabetes (Victoza) starts at 0.6 mg daily, escalating to 1.2 mg and potentially 1.8 mg if needed, while liraglutide for weight management (Saxenda) follows a schedule from 0.6 mg to 3.0 mg daily (via 1.2 mg, 1.8 mg, and 2.4 mg steps)

CagriSema , combining semaglutide with cagrilintide (an amylin analog), represents another approach

Youll get a text with next steps when its ready

More Energy, Less Brain Fog As blood sugar stabilizes and inflammation drops, many women report feeling more mentally clear and energized especially after the first few weeks on treatment

Retatrutide is the most powerful weight loss peptide in clinical development right now, a triple agonist that hits GLP-1, GIP, and glucagon receptors simultaneously